Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response - Trial NCT06239727
Access comprehensive clinical trial information for NCT06239727 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 593 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 3
Feb 20, 2024
Feb 20, 2030
Primary Outcome
Locoregional failure-free survival (LRFFS)
Summary
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to
 investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and
 immunotherapy on patients' prognosis and complication compared with conventional-dose
 radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage
 III NPC patients screened out according to the treatment response.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06239727
Non-Device Trial